格隆汇11月28日丨嘉应制药(002198.SZ)在投资者互动平台表示，公司部分产品涉及感冒、咽喉肿痛 类，目前生产依据计划和市场情况有序进行。 ...

Core Viewpoint - The recent strong performance of the pharmaceutical retail and distribution sectors in A-shares and Hong Kong stocks is driven by an unusually high level of autumn flu activity, leading to heightened market expectations for the earnings resilience of pharmaceutical companies [1][2]. Group 1: Market Performance - The flu cases in northern provinces reached 5.1% of total emergency visits as of November 2, the highest since February 2025, while southern provinces saw flu cases rise to 4.6%, the highest since June 2025 [1]. - The significant increase in flu activity compared to the previous year has led to a surge in demand expectations for cold, fever, and antiviral medications [1]. - The pharmaceutical commercial sector, acting as a key link between drug production and end consumption, is expected to experience a short-term boost in business volume, including retail pharmacy sales and distribution volumes [1]. Group 2: Investment Trends - Market funds are proactively positioning themselves in the pharmaceutical commercial sector, which is currently valued relatively low, based on the anticipated earnings improvements due to the flu outbreak [1]. - The overall valuation recovery of the sector is driven by improved fundamental expectations, with market participants keenly capturing this change [1]. - Within this rally, companies with stronger supply chain capabilities, broader network coverage, or unique business models are favored by investors, with leading stocks like Dazhenglin and Yifeng Pharmacy showing active performance [2]. Group 3: Long-term Considerations - The sustainability of the sector's performance is closely tied to corporate earnings, and investors are advised to focus on companies that enhance their core competitiveness and possess resilient business models amid industry changes [2]. - While short-term event-driven opportunities are important, attention should also be given to the long-term value of these companies [2].